Fig. 1

Monthly and overall least square (LS) mean changes from baseline in the number of migraine headache days during the treatment period in a the total population^#, b patients with CM^# and c patients with EM^#. ^#Patients who had failed 3–4 preventive medication categories due to inadequate efficacy (after at least 2 months at maximum tolerated dose), or safety or tolerability reasons within the last 10 years. ****P ≤ .0001, ***P ≤ .001, **P ≤ .01 versus placebo. Abbreviations: CM, chronic migraine; EM, episodic migraine; GMB, galcanezumab; n, number of patients with non-missing baseline value and at least one post-baseline value; SE, standard error